Results 201 to 210 of about 67,119 (304)

ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance

International Journal of Cancer, Volume 159, Issue 2, Page 410-422, 15 July 2026.
What's new? Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic precursor to multiple myeloma, sharing substantial genetic features with overt malignancy. Given evidence implicating autophagy in myeloma risk, this study examined whether genetic variations in autophagy‐related genes influence MGUS susceptibility.
José Manuel Sánchez‐Maldonado, Angelica Macauda, Antonio José Cabrera‐Serrano, Hauke Thomsen, Murat Güler, Rob Ter Horst, Bethany van Guelpen, Pavel Vodicka, Stefano Landi, Subhayan Chattopadhyay, Pelin Ünal, Lucía Ruiz‐Durán, Delphine Casabonne, Hartmut Goldschmidt, Istemi Serin, María Carretero‐Fernández, Elena Cabezudo, Fernando Reyes‐Zurita, Aaron D. Norman, Ramón García‐Sanz, Gabriele Capurso, Per Hoffmann, Ulrika Pettersson‐Kymmer, Francisco Jiménez‐Romera, S. Vincent Rajkumar, Niels Weinhold, Ludmila Vodickova, Christian Langer, Angelika Stein, Abdulkadir Karismaz, Victor Moreno, Markus M. Nöthen, Karl‐Heinz Jöckel, Francesca Tavano, Joaquín Martínez‐López, Shaji K. Kumar, Juan Francisco Gutiérrez‐Bautista, Daniela Basso, Florentin Späth, Yolanda Benavente, Michelle A. T. Hildebrandt, Börge Schmidt, Tereza Sevcikova, Rui Manuel Vieira Reis, Yang Li, Miguel Ángel López‐Nevot, Mihai G. Netea, Daniele Campa, Alyssa Clay‐Gilmour, Susan L Slager, Kari Hemminki, Celine M Vachon, Asta Försti, Federico Canzian, Juan Sainz   +54 more
wiley   +1 more source

NAD⁺ metabolism at the host-virus interface. [PDF]

J Gen Virol
Jhandai P, Vaddadi K, Liu L.
europepmc   +1 more source

Navigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

American Journal of Hematology, Volume 101, Issue 7, Page 1433-1439, July 2026.
ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz, Winfried Alsdorf, Lisa Leypoldt, Piet Sonnemann, Christoph Schaefers, Jule Artzenroth, Marie Harzer, Abdulaziz Kamili, Leandra Bartke, Leon Cords, Jan Vorwerk, Theo Leitner, Markus Maulhardt, Kerstin Brinkert, Annamaria Brioli, Tim Richardson, Udo Holtick, Stefan M. Hillmann, Hans Salwender, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Ricardo Kosch   +22 more
wiley   +1 more source

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference. [PDF]

Blood Neoplasia
Lustig M, Kowol M, Hartmann AM, van der Peet IC, Jansen MJH, Iben K, Winterberg D, Krohn S, Baumann N, Rösner T, Bendig S, Hahn C, Wurm AA, Gehlert CL, Denker M, Suwanchaikasem P, Macarrón Palacios A, Schwartz S, Brüggemann M, Burger R, Schmitt K, Klausz K, Valerius O, Stölzel F, Bastian L, Baldus CD, Peipp M, Leusen JHW, Schewe DM, Valerius T.   +29 more
europepmc   +1 more source

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights

American Journal of Hematology, Volume 101, Issue 7, Page 1575-1588, July 2026.
CTC offer a minimally invasive widow into systemic myeloma biology, overcoming the sampling bias of bone marrow biopsies. Their prognostic value at diagnosis, potential role in MRD monitoring, and ability to capture clonal evolution highlight them as actionable biomarkers for future precision medicine.
Benjamin Podvin, Bruno Paiva, Irene M. Ghobrial, Salomon Manier   +3 more
wiley   +1 more source

The Host NADase CD38 Promotes JEV Replication by Targeting the NAD+/SIRT1 Axis. [PDF]

Microorganisms
Yang Y, Zhang R, Li X, Liu X, Dai Y, Gu Y, Li J, Chen H, Zheng Y, Wu R.   +9 more
europepmc   +1 more source

The Dual Roles of Regulatory B Cells in Infection, Cancer, and Immunity

MedComm, Volume 7, Issue 7, July 2026.
Regulatory B cells maintain immune homeostasis via suppressive cytokines and surface molecules like PD‐L1. While beneficially suppressing autoimmunity and promoting transplant tolerance, these identical mechanisms detrimentally attenuate antipathogen and antitumor immune responses.
Anni Feng, Qilong Li, Ning Jiang, Qijun Chen   +3 more
wiley   +1 more source

Type III CD38 is present in the membrane of neurosecretory vesicles and has a cytosol-facing catalytic domain in primate oxytocin neurons. [PDF]

J Neuroendocrinol
Miyamoto T, Matsushima A, Otubo A, Song C, Murata K, Oti T, Sakamoto H.   +6 more
europepmc   +1 more source

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives

European Journal of Haematology, Volume 117, Issue 1, Page 42-54, July 2026.
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myeloma. [PDF]

Hemasphere
Raoof R, Dal Collo G, Simon-Molas H, Tzortzi P, Kulaj K, Demirez EN, Massaro C, Poels R, Korst CLBM, O'Neill CA, Bruins WSC, Broekmans MEC, Behradkia P, Krevvata M, Zweegman S, Kater AP, Baglio SR, Mutis T, van de Donk NWCJ.   +18 more
europepmc   +1 more source